Dolasetron

332 interactions 1 explained in plain English 421 cited references

Also sold as: Anzemet Anzemet®

About Dolasetron

Dolasetron is used to prevent nausea and vomiting caused by cancer chemotherapy. Dolasetron is in a class of medications called serotonin 5-HT3 receptor antagonists. It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. Read the full Dolasetron drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Piperaquine Phenelzine Saquinavir Pimozide Mesoridazine Sparfloxacin

16 Contraindicated 314 Major 1 Moderate 1 Minor

All (332) Contraindicated (16) Major (314) Moderate (1) Minor (1)

Major

Dolasetron Gemifloxacin Factive An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dolasetron Gepirone Exxua Increased risk of serotonin syndrome and an increased risk of QT interval prolongation and cardiac arrhythmias Details Dolasetron Gepotidacin Blujepa An increased risk of QT interval prolongation Details Dolasetron Givinostat Duvyzat Increased risk of QT interval prolongation and torsade de pointes Details Dolasetron Glasdegib Daurismo Increased risk of QT interval prolongation Details Dolasetron Goserelin Increased risk of QT interval prolongation Details Dolasetron Granisetron Increased risk of serotonin syndrome and QT-interval prolongation Details Dolasetron Halofantrine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dolasetron Haloperidol An increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Dolasetron Halothane An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dolasetron Histrelin Supprelin Increased risk of QT interval prolongation Details Dolasetron Hydrocodone Hysingla An increased risk of serotonin syndrome Details Dolasetron Hydromorphone Dilaudid Increased risk of serotonin syndrome Details Dolasetron Hydroquinidine Cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dolasetron Hydroxyamphetamine An increased risk of serotonin syndrome Details Dolasetron Hydroxychloroquine Plaquenil Increased risk of QT interval prolongation Details Dolasetron Hydroxytryptophan Increased risk of serotonin syndrome Details Dolasetron Hydroxyzine An increased risk of QT interval prolongation Details Dolasetron Ibutilide Corvert Cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Dolasetron Iloperidone Fanapt An increased risk of QT interval prolongation Details Dolasetron Imipramine Increased risk of serotonin syndrome and QT-interval prolongation Details Dolasetron Inotuzumab Ozogamicin Besponsa Increased risk of QT interval prolongation Details Dolasetron Iproniazid Increased risk of serotonin syndrome Details Dolasetron Isocarboxazid Marplan Increased risk of serotonin syndrome Details Dolasetron Isoflurane Fluriso An increased risk of QT prolongation and torsades de pointes Details Dolasetron Isradipine DynaCirc® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dolasetron Itraconazole Sporanox An increased risk of QT interval prolongation and torsade de pointes Details Dolasetron Ivabradine Corlanor Increased risk of QT prolongation Details Dolasetron Ivosidenib Tibsovo An increased risk of QT interval prolongation Details Dolasetron Ketoconazole Extina Increased risk of QT interval prolongation Details Dolasetron Kratom An increased risk of serotonin syndrome Details Dolasetron Lacosamide Motpoly An increased risk of PR interval prolongation, AV block, bradycardia, and ventricular tachyarrhythmia Details Dolasetron Lapatinib Tykerb An increased risk of QT interval prolongation Details Dolasetron Lasmiditan Reyvow Increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes) Details Dolasetron Lefamulin Xenleta Increased risk of QT interval prolongation Details Dolasetron Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Dolasetron Leuprolide Eligard Increased risk of QT interval prolongation Details Dolasetron Levofloxacin Levaquin Increased risk of QT interval prolongation Details Dolasetron Levomilnacipran Increased risk of serotonin syndrome Details Dolasetron Levorphanol Xyvona An increased risk of serotonin syndrome Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.